Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope to stop deadly skin Cancer's return

NCT ID NCT02362594

Summary

This study tested whether a drug called pembrolizumab, given after surgery, could help prevent melanoma skin cancer from coming back in high-risk patients. Over 1,000 participants who had their cancer surgically removed were randomly assigned to receive either the drug or a placebo. The main goal was to see if the drug could extend the time patients lived without their cancer returning.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

Explore the condition pages connected to this study.